

**F-627**

“ ” Evive Biotech Ltd.

-Fc “F-627”  
2021 5 27  
(FDA) F-627 F-627

F-627 Di-Kine™  
Fc CHO rhG-CSF  
F-627

2017 10 F-627 III “05 ”  
FDA SPA FDA F-627 05  
2018 1 F-627

III “04 ”

2020 1 5

F-627 III F-627

III

2020 6

05

III

2020 7

05

F-627

I II

III

2021 3 30 F-627

FDA BLA

2020 1 6

2020 6 29

2020 7 8

2021 3 31

F-627 III

2020-001

F-627 III

2020-044

F-627

III

2020-046

F-627

2021-038

FDA

21 CFR 601.2 a

FDA

BLA

Prescription Drug User Fee

Act (PDUFA) VI

2022 3 30

FDA F-627

FDA

F-627

FDA

FDA

2021 5 29